Pauline E. Kargopolova

Pauline E. Kargopolova

Auto-generated profile, based on publicly available information

Pauline E. Kargopolova

GENERIUM JSC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Regulatory Research and Medicine Evaluation
Verified
Journal Article
Closed access
YNYu. A. Nikonova
Yu. A. Nikonova
SAS. G. Abbasova
S. G. Abbasova
PKP. E. Kargopolova
P. E. Kargopolova
OSOlga Strizhakova
Olga Strizhakova
ILIvan Lyagoskin
Ivan Lyagoskin
Andrei Sergeevitch PershinAndrei Sergeevitch Pershin
Andrei Sergeevitch Pershin
INTRODUCTION. Bioanalytical techniques are characterised by greater variability and lower stability than physicochemical methods because live test systems are inherently labile. Since regulatory standards do not establish a unified approach, the selection of system suitability criteria and acceptance criteria for test results is based on validation studies.AIM. This study aimed to validate an analytical procedure for evaluating the biological activity of a medicinal product based on the investigational tocilizumab biosimilar GNR-087 and determine the quantitative limits for system suitability criteria and acceptance criteria for test results.MATERIALS AND METHODS. The biological activity of the investigational tocilizumab biosimilar was assessed by the inhibition of IL-6-induced secreted embryonic alkaline phosphatase (SEAP) expression by HEK-Blue™ IL-6 cells. Statistical processing of the obtained results was performed using Prism 6.0 software.RESULTS. The specificity of the analytical procedure was confirmed by the dose-dependent inhibition of IL-6-induced SEAP expression by cells observed with tocilizumab. The analytical procedure was linear, with a coefficient of determination R2≥ 0.99. The precision of the analytical procedure was satisfactory; its repeat ability varied from 2 to 9%, and its intermediate precision was 14%. The recovery coefficients (Rc) for spiked samples simulating activity levels of 60–140%, including blinded samples, ranged from 80 to 120%. The theoretical values of relative potency (RP) were within the confidence intervals of the mean relative potency estimates, which confirmed the accuracy of the analytical procedure. The validation confirmed the robustness of the analytical procedure to controlled variations, including the use of reporter cells at different passages (with a coefficient of variation for relative potency estimates (CVRP) of 10%), different IL-6 lots (with a CVRP of 1%), and different SEAP detection reagent lots (with a CVRP of 3%); the Rc remained in the range of 80–120% of the nominal RP value.CONCLUSIONS. The analytical procedure for evaluating the biological activity of the investigational tocilizumab biosimilar meets the validation criteria, including accuracy, linearity, precision, specificity, and robustness. The study established system suitability criteria and acceptable limits for biological assay results. This analytical procedure can be used both for routine biological activity control and for demonstrating the biosimilarity of new medicinal products to the original (reference) tocilizumab-based medicinal product.

15 November 2022 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
ILIvan Lyagoskin
Ivan Lyagoskin
PKPauline E. Kargopolova
Pauline E. Kargopolova
DODmitry A. Obyedkov
Dmitry A. Obyedkov
IEIrina Yu. Egorova
Irina Yu. Egorova
RSRahim Shukurov
Rahim Shukurov
ОАОбъедков Дмитрий Анатольевич
Объедков Дмитрий Анатольевич
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV (2019-Novel Coronavirus) is a strain of coronavirus from the genus Betacoronavirus, discovered in China at the end of 2019 in patients with pneumonia. Coronavirus infection COVID-19 (COrona VIrus Disease 2019) caused by coronavirus 2019 (COVID-19) has spread around the world at a very fast pace, with death toll exceeding more than 5.2 million people worldwide. Limited success in developing new drugs as well as use of existing drugs for the treatment of COVID-19 resulted in situation when the main prevention measures for a long time were based on testing and isolation of sick subjects, which started to reverse due to vaccination. Monitoring the formation of humoral and T-cell population immunity against the SARS-CoV-2 virus during the COVID-19 pandemic is a necessary element for epidemiological surveillance. ELISA-based methods are widely used to assess humoral immunity, and various test systems including ELISPOT (Enzyme-Linked ImmunoSpot) are used to analyze cellular immunity. The ELISPOT assay is a highly sensitive and specific method for quantifying individual cytokine-secreting T cells after being stimulated with a specific antigen. TigraTest SARS-CoV-2 Test assessing release of interferon gamma in vitro to detect peripheral blood T-lymphocytes that specifically respond to the SARS-CoV-2 virus antigens manufactured by GENERIUM JSC, is created on the ELISPOT platform. This study describes the procedure for laboratory validation of this test system to analyze the following parameters: specificity of antibody pair, effect of interfering substances, sensitivity and specificity, precision, stability of blood samples till isolation of target cells. The developed test system showed high diagnostic sensitivity and specificity. The specificity of TigraTest SARS-CoV-2 was 100%, the sensitivity for subjects immunized with the Gam-COVID-Vac vaccine (Sputnik V) was 91.67%, and the sensitivity in convalescent COVID-19 patients was 95.45%. At the same time, the data variability both during within and between series comparison did not exceed 25%, whereas 24-hour storage of peripheral blood samples at (1825)С after blood collection followed by isolation of target cells did not affect the test results.